Case ID: f-appx_236/html/0608-01.html
Source: Caselaw Access Project
Author: {"author": "LINN, Circuit Judge.", "license": "Public Domain", "url": "https://static.case.law/"}
Date Created: 2024-08-24T03:29:51.129683

PFIZER INC., Plaintiff-Appellee, v. MYLAN LABORATORIES, INC. and Mylan Pharmaceuticals, Inc., Defendants-Appellants.
    No. 2007-1194.
    United States Court of Appeals, Federal Circuit.
    June 5, 2007.
    David J. Harth, Heller Ehrman, LLP, Madison, WI, E. Anthony Figg, Steven M. Lieberman, Minaksi Bhatt, Rothwell, Figg, Ernst & Manbeck, Shannon M. Blood-worth, Heller Ehrman LLP, Washington, DC, for Defendants-Appellants.
    Richard G. Greco, Milton Sherman, Daniel Boglioli, Kaye Scholer LLP, New York, NY, Donald B. Cameron, Troutman Sanders LLP, David O. Bickart, Kaye Scholer LLP, Washington, DC, for Plaintiff-Appellee.
    Before SCHALL, GAJARSA, and LINN, Circuit Judges.
   ORDER

LINN, Circuit Judge.

Mylan Laboratories, Inc. and Mylan Pharmaceuticals, Inc. (Mylan) move for summary reversal of the judgment and amended judgment of the United States District Court for the Western District of Pennsylvania. Pfizer Inc. opposes.

On March 22, 2007, in Pfizer, Inc. v. Apotex, Inc., 480 F.3d 1348 (Fed.Cir.2007), this court held that the asserted claims of Pfizer’s patent are invalid. On May 21, 2007, this court denied Pfizer’s petition for rehearing en banc in that case and the mandate issued.

Upon consideration thereof,

IT IS ORDERED THAT:

(1) Mylan’s motion for summary reversal is granted. The district court’s judgment and amended judgment are reversed.

(2) Each side shall bear its own costs.